BlackRock Institutional Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlackRock Institutional Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$74.1M	Buy	1,054,386 +146,833	+16%	+$10.4M	0.01%	1102
2016 Q3	$64.4M	Buy	907,553 +28,552	+3%	+$1.82M	0.01%	1128
2016 Q2	$43M	Sell	879,001 -12,939	-1%	-$837K	0.01%	1332
2016 Q1	$56.5M	Buy	891,940 +602	+0.1%	+$39.4K	0.01%	1145
2015 Q4	$100M	Buy	891,338 +37,595	+4%	+$3.76M	0.02%	841
2015 Q3	$82.2M	Buy	853,743 +128,534	+18%	+$14.7M	0.01%	947
2015 Q2	$74.3M	Buy	725,209 +212,086	+41%	+$16.5M	0.01%	1079
2015 Q1	$31.9M	Buy	513,123 +19,951	+4%	+$1.11M	0.01%	1611
2014 Q4	$21.6M	Buy	493,172 +25,976	+6%	+$1.19M	﹤0.01%	1849
2014 Q3	$26.4M	Buy	467,196 +387,071	+483%	+$19.5M	﹤0.01%	1704
2014 Q2	$3.6M	Sell	80,125 -25,136	-24%	-$1.03M	﹤0.01%	2928
2014 Q1	$5.15M	Buy	+105,261	New	+$5.42M	﹤0.01%	2767

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock Institutional Trust's RARE Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Ultragenyx Pharmaceutical (RARE) stake by 16% in Q4 2016, buying an estimated $10.4M and bringing the position to 1,054,386 shares worth $74.1M. The position accounts for 0.01% of the portfolio, ranked #1102.

BlackRock Institutional Trust first reported a position in RARE in Q1 2014 and has held it in 12 quarters since. The position peaked at $100M in Q4 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

BlackRock Institutional Trust held 1,054,386 shares of Ultragenyx Pharmaceutical worth $74.1M as of Q4 2016.
BlackRock Institutional Trust bought 146,833 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $10.4M.
Ultragenyx Pharmaceutical made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1102 holding.
BlackRock Institutional Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Ultragenyx Pharmaceutical position peaked at $100M in Q4 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.